Check out our comprehensive educational activities here

Development of a Novel NGS-Based Assay for MRD in FLT3-ITD AML

Dr. Levis explains the development of a novel next-generation sequencing assay for MRD in FLT3-ITD mutated AML and its clinical application in patients treated with chemotherapy plus FLT3 inhibitors.

Published on January 4, 2019 in Treatment

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Dr. Stein briefly covers the Beat AML Master Study, including how enasidenib impacts patients with IDH2 mutant AML.

Published on January 4, 2019 in Treatment

An overview of the recently approved combination of venetoclax with azacitidine or decitabine or low-dose cytarabine and where this new option fits in the current treatment paradigm

In this activity, Dr. Harry Erba discusses the combination of venetoclax with azacitidine or decitabine or low-dose cytarabine and where this new option fits in the current treatment paradigm for AML.

Published on December 13, 2018 in Treatment

What are the future options for treating older patients who are not eligible for induction chemotherapy?

Dr. Fathi discusses avenues for approaching treatment in your older patient with AML when intensive induction chemotherapy is not an option.

Published on December 10, 2018 in Treatment

How do I incorporate FLT3 and IDH inhibitor therapy into my practice?

Dr. Fathi briefly reviews the incorporation of targeted therapies (FLT3 and IDH inhibitors) into the management of acute myeloid leukemia.

Published on November 26, 2018 in Treatment

An expert update on the role of CAR T therapy in AML

Dr. Park briefly explores the challenges and potential of CAR T cell therapy in AML.

Published on November 14, 2018 in Treatment

How do cytogenetics and molecular risk guide your treatment decisions?

Dr. Desai discusses the heterogeneity of AML and why it's so important to have a clear understanding of a patient's genetic profile and risks.

Published on November 5, 2018 in Treatment

Third-generation FLT3 inhibitors in clinical development

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Published on October 18, 2018 in Treatment

Clinical Challenges with New and Emerging IDH1/IDH2 Inhibitors

Dr. Cortes discusses what to look for when managing patients being treated with an IDH1 or IDH2 inhibitor.

Published on September 24, 2018 in Treatment

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibitor

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.

Published on September 20, 2018 in Treatment